Vimarsana
Biggest News Aggregation in the World

Page 2 - Key Markers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Key Markers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Key Markers Today - Breaking & Trending Today

Poxel SA: Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting 2022 - Vimarsana News

Poxel SA: Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting 2022

Late-breaking abstract selected by AASLD as one of the "Best of the Liver Meeting" for 2022 Phase 2 for PXL065 in NASH achieved the primary efficacy endpoint for liver fat content reduction

Poxel SA: Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone - Vimarsana News

Poxel SA: Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks - Vimarsana News

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution